CD44-Targeted pH-Responsive Nanoenzyme-Liposome Complexes Co-Delivering Ceria Nanozymes and Cryptotanshinone To Alleviate Liver Fibrosis
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Kai Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Modern Traditional Chinese Medicine Industry, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R…. Hauptthemen laut MEDLINE: Phenanthrenes, Liver Cirrhosis, Hyaluronan Receptors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Sichuan Provincial Administration of Traditional Chinese Medicine, Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Liver fibrosis, driven by unresolved inflammation and oxidative stress, lacks effective therapies. We developed hyaluronic acid (HA)-functionalized, pH-sensitive liposomes (HA-CeCPL) coencapsulating cryptotanshinone (CTS), an NLRP3 inflammasome inhibitor, and biomineralized ceria nanozymes (Ce-BSA) for synergistic liver fibrosis therapy. HA-CeCPL demonstrated pH-responsive payload release and preferential accumulation in fibrotic livers via CD44-mediated targeting of macrophages. In vitro, HA-CeCPL enhanced cellular uptake in macrophages, suppressed NLRP3 inflammasomes activation, and reduced IL-1β secretion. Meanwhile, the nanozyme-liposome complexs effectively scavenged reactive oxygen species (ROS), thus attenuating HSC activation, as evidenced by downregulation of α-smooth muscle actin. In vivo, HA-CeCPL exhibited superior hepatic targeting in CCl4-induced fibrotic mice. It significantly ameliorated liver injury, restored liver function, reduced collagen deposition, and suppressed α-SMA expression. Furthermore, HA-CeCPL interfered with NLRP3 inflammasome signaling and pro-inflammatory cytokine cascades, breaking the inflammation-fibrosis cycle. These results demonstrate that the targeted dual-pathway strategy (simultaneously quenching ROS and blocking NLRP3 activation) synergistically resolves liver fibrosis, offering a promising nanotherapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, College of Modern Traditional Chinese Medicine Industry, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R. China.
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R. China.
- Lab for Innovation & Effective Uses of Chinese Drug Germplasm Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R. China.
- College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, P. R. China.
- Chongqing Key Laboratory of Sichuan-Chongqing Co-Construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chongqing 400000, P. R. China.
ORCID-Profile: Kai Liu, Yuxin Zhao, Xiaofang Li
Förderung
- Sichuan Provincial Administration of Traditional Chinese Medicine
- Science and Technology Department of Sichuan Province
Zitieren
APA
Liu, K., Zhao, Y., Luo, N., Luo, J., & Li, X. (2026). CD44-Targeted pH-Responsive Nanoenzyme-Liposome Complexes Co-Delivering Ceria Nanozymes and Cryptotanshinone To Alleviate Liver Fibrosis. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01175
Vancouver
Liu K, Zhao Y, Luo N, Luo J, Li X. CD44-Targeted pH-Responsive Nanoenzyme-Liposome Complexes Co-Delivering Ceria Nanozymes and Cryptotanshinone To Alleviate Liver Fibrosis. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01175
BibTeX
@article{Liu2026,
author = {Liu, Kai and Zhao, Yuxin and Luo, Nini and Luo, Jia and Li, Xiaofang},
title = {CD44-Targeted pH-Responsive Nanoenzyme-Liposome Complexes Co-Delivering Ceria Nanozymes and Cryptotanshinone To Alleviate Liver Fibrosis},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01175}
}
EUVIMED